The University of Southampton
University of Southampton Institutional Repository

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Background: In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and collectively exhaustive list of diseases and injuries. Methods: GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories. Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence, prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every metric using the 25th and 975th ordered 1000 draw values of the posterior distribution. Findings: Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared with the 1990–2010 time period, with the greatest annualised rate of decline occurring in the 0–9-year age group. Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough (ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked tenth). In adolescents aged 10–24 years, three injury causes were among the top causes of DALYs: road injuries (ranked first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10–24 years were also in the top ten in the 25–49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain (fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the top-ranked causes of DALYs in both the 50–74-year and 75-years-and-older age groups. Since 1990, there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries. In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI. Interpretation: As disability becomes an increasingly large component of disease burden and a larger component of health expenditure, greater research and development investment is needed to identify new, more effective intervention strategies. With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of universal and more geographically specific influences on health reinforces the need for regular reporting on population health in detail and by underlying cause to help decision makers to identify success stories of disease control to emulate, as well as opportunities to improve. Funding: Bill & Melinda Gates Foundation.
0140-6736
1204-1222
Abbafati, Cristiana
521168a7-4836-42f0-b082-7b21c8093724
Abbas, Kaja M.
43cf5abc-77b4-4aea-809d-b9b4f0e48b17
Abbasi-Kangevari, Mohsen
6605d315-6856-461b-a501-4a38e4ab9918
Abd-Allah, Foad
67ee336c-84ba-4ff1-9324-28a02b45412e
Abdelalim, Ahmed
705987b2-ce4d-4573-b722-e0b4d145670a
Abdollahi, Mohammad
96ec68db-6302-4216-9aaf-9951a44be8b8
Abdollahpour, Ibrahim
8a1b3f3c-497f-4297-adc2-03055e798176
Abegaz, Kedir Hussein
6eb2ac98-d880-4cb3-843f-8e6b7cac1d5b
Abolhassani, Hassan
f02011b5-df85-4627-94c7-1365a4241b95
Aboyans, Victor
49a8cbaa-c577-4047-90af-3cdae75aa1f5
Abreu, Lucas Guimarães
23690a30-3320-46af-bd14-7c17c06a40ea
Abrigo, Michael R.M.
11213002-2bb2-420c-9087-c251164bf353
Abualhasan, Ahmed
0d2e772b-b31f-4304-8022-ebe47d78dd1d
Abu-Raddad, Laith Jamal
645c0199-ac7e-4e0d-97b6-829eb7f2f388
Abushouk, Abdelrahman I.
75af6533-bad5-4233-8403-c8383b39c51b
Adabi, Maryam
ad7550fc-d5d5-4fe4-8968-48665f2ebfb9
Adekanmbi, Victor
46d212c3-bfe7-468e-8f11-0574bbbb90bd
Adeoye, Abiodun Moshood
ec5e4a2d-86a4-4541-a16a-1d9366e88d96
Adetokunboh, Olatunji O.
f80bd9b5-5b52-4f3e-9a3d-2cfb4ee24ab1
Adham, Davoud
bf7a0903-f574-4200-a47d-4f7ed2a5bba5
Advani, Shailesh M.
7c0591f3-1783-4779-86a3-8532038f3bc3
Afshin, Ashkan
0cdfa673-855e-484f-9d48-4dcfe0d1a59c
Agarwal, Gina
857b681f-eb3d-44a7-8f21-1ade6a01a9cc
Aghamir, Seyed Mohammad Kazem
dce0a3f7-1671-4884-8cab-fb55d050d8a8
Agrawal, Anurag
f7d3c8c9-b6ff-4260-b8b1-2aad8fa116b0
Ahmad, Tauseef
655b560c-a5b7-4562-ace0-54e62f14685c
Ahmadi, Keivan
64f3fe5b-fdd6-42ea-9c11-75cdd1cc7775
Ahmadi, Mehdi
c974cd4d-bd6e-45c9-aec9-1b8f168cdde4
Ahmadieh, Hamid
f828ae31-8e90-4368-8405-dbb30f9c21f6
Ahmed, Muktar Beshir
e1af2a0d-079f-4e56-b325-714bc9b1e318
Akalu, Temesgen Yihunie
cfc98983-56d3-4ab3-8964-d5e86338134e
Akinyemi, Rufus Olusola
1f73524a-e377-4df4-acc9-69b5cefe408d
Akinyemiju, Tomi
c70b01a9-1434-4611-9dd5-be253673431e
Akombi, Blessing
17335f9c-e6fa-4775-8faf-8f7562ed2b92
Akunna, Chisom Joyqueenet
500e01fc-7e84-4f49-bc2e-645e0a3800df
Alahdab, Fares
f446c0b7-f9d5-48f7-9053-40243513997a
Al-Aly, Ziyad
99c680ae-f71e-475f-90b8-736dc2333782
Alam, Khurshid
3d76f8f9-aa4b-43e5-883a-a34d532a29f3
Alam, Samiah
882e6c25-d0eb-4e59-b3e2-c258b7b3ea1d
Alam, Tahiya
a2c07547-9702-4a83-b1f5-1a0409c5a97c
Alanezi, Fahad Mashhour
dc0f1b9d-f0e9-44f1-bd12-46477958435a
Alanzi, Turki M.
9b26c002-86dc-4847-8051-404c5e577ebd
Alemu, Biresaw Wassihun
ee62d13b-9268-4172-96d9-e2cc3fb112e3
Gething, Peter W.
65de5042-a466-460c-999c-df4af842780d
Hasan, Md Mehedi
47aa5bdc-58c1-4384-a688-5584fd40e3de
Liu, Yang
125eb4d6-0931-4905-a3bb-c09ef35e75c1
Roberts, Nicholas L.S.
27e94fa0-ad20-4a43-a10d-67b272071ab6
Salomon, Joshua A.
af51ebe8-275d-44a2-9bc6-2afc10a09d7c
Wang, Yuan Pang
332ff320-0449-4df8-a3db-2ac6020cff7f
Lim, Stephen S.
99ad2619-c72c-4c23-a352-33f473f1a30f
Lee, Paul
02620eab-ae7f-4a1c-bad1-8a50e7e48951
et al.
Abbafati, Cristiana
521168a7-4836-42f0-b082-7b21c8093724
Abbas, Kaja M.
43cf5abc-77b4-4aea-809d-b9b4f0e48b17
Abbasi-Kangevari, Mohsen
6605d315-6856-461b-a501-4a38e4ab9918
Abd-Allah, Foad
67ee336c-84ba-4ff1-9324-28a02b45412e
Abdelalim, Ahmed
705987b2-ce4d-4573-b722-e0b4d145670a
Abdollahi, Mohammad
96ec68db-6302-4216-9aaf-9951a44be8b8
Abdollahpour, Ibrahim
8a1b3f3c-497f-4297-adc2-03055e798176
Abegaz, Kedir Hussein
6eb2ac98-d880-4cb3-843f-8e6b7cac1d5b
Abolhassani, Hassan
f02011b5-df85-4627-94c7-1365a4241b95
Aboyans, Victor
49a8cbaa-c577-4047-90af-3cdae75aa1f5
Abreu, Lucas Guimarães
23690a30-3320-46af-bd14-7c17c06a40ea
Abrigo, Michael R.M.
11213002-2bb2-420c-9087-c251164bf353
Abualhasan, Ahmed
0d2e772b-b31f-4304-8022-ebe47d78dd1d
Abu-Raddad, Laith Jamal
645c0199-ac7e-4e0d-97b6-829eb7f2f388
Abushouk, Abdelrahman I.
75af6533-bad5-4233-8403-c8383b39c51b
Adabi, Maryam
ad7550fc-d5d5-4fe4-8968-48665f2ebfb9
Adekanmbi, Victor
46d212c3-bfe7-468e-8f11-0574bbbb90bd
Adeoye, Abiodun Moshood
ec5e4a2d-86a4-4541-a16a-1d9366e88d96
Adetokunboh, Olatunji O.
f80bd9b5-5b52-4f3e-9a3d-2cfb4ee24ab1
Adham, Davoud
bf7a0903-f574-4200-a47d-4f7ed2a5bba5
Advani, Shailesh M.
7c0591f3-1783-4779-86a3-8532038f3bc3
Afshin, Ashkan
0cdfa673-855e-484f-9d48-4dcfe0d1a59c
Agarwal, Gina
857b681f-eb3d-44a7-8f21-1ade6a01a9cc
Aghamir, Seyed Mohammad Kazem
dce0a3f7-1671-4884-8cab-fb55d050d8a8
Agrawal, Anurag
f7d3c8c9-b6ff-4260-b8b1-2aad8fa116b0
Ahmad, Tauseef
655b560c-a5b7-4562-ace0-54e62f14685c
Ahmadi, Keivan
64f3fe5b-fdd6-42ea-9c11-75cdd1cc7775
Ahmadi, Mehdi
c974cd4d-bd6e-45c9-aec9-1b8f168cdde4
Ahmadieh, Hamid
f828ae31-8e90-4368-8405-dbb30f9c21f6
Ahmed, Muktar Beshir
e1af2a0d-079f-4e56-b325-714bc9b1e318
Akalu, Temesgen Yihunie
cfc98983-56d3-4ab3-8964-d5e86338134e
Akinyemi, Rufus Olusola
1f73524a-e377-4df4-acc9-69b5cefe408d
Akinyemiju, Tomi
c70b01a9-1434-4611-9dd5-be253673431e
Akombi, Blessing
17335f9c-e6fa-4775-8faf-8f7562ed2b92
Akunna, Chisom Joyqueenet
500e01fc-7e84-4f49-bc2e-645e0a3800df
Alahdab, Fares
f446c0b7-f9d5-48f7-9053-40243513997a
Al-Aly, Ziyad
99c680ae-f71e-475f-90b8-736dc2333782
Alam, Khurshid
3d76f8f9-aa4b-43e5-883a-a34d532a29f3
Alam, Samiah
882e6c25-d0eb-4e59-b3e2-c258b7b3ea1d
Alam, Tahiya
a2c07547-9702-4a83-b1f5-1a0409c5a97c
Alanezi, Fahad Mashhour
dc0f1b9d-f0e9-44f1-bd12-46477958435a
Alanzi, Turki M.
9b26c002-86dc-4847-8051-404c5e577ebd
Alemu, Biresaw Wassihun
ee62d13b-9268-4172-96d9-e2cc3fb112e3
Gething, Peter W.
65de5042-a466-460c-999c-df4af842780d
Hasan, Md Mehedi
47aa5bdc-58c1-4384-a688-5584fd40e3de
Liu, Yang
125eb4d6-0931-4905-a3bb-c09ef35e75c1
Roberts, Nicholas L.S.
27e94fa0-ad20-4a43-a10d-67b272071ab6
Salomon, Joshua A.
af51ebe8-275d-44a2-9bc6-2afc10a09d7c
Wang, Yuan Pang
332ff320-0449-4df8-a3db-2ac6020cff7f
Lim, Stephen S.
99ad2619-c72c-4c23-a352-33f473f1a30f
Lee, Paul
02620eab-ae7f-4a1c-bad1-8a50e7e48951

Abbafati, Cristiana, Abbas, Kaja M., Abbasi-Kangevari, Mohsen and Lee, Paul , et al. (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 396 (10258), 1204-1222. (doi:10.1016/S0140-6736(20)30925-9).

Record type: Article

Abstract

Background: In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and collectively exhaustive list of diseases and injuries. Methods: GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories. Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence, prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every metric using the 25th and 975th ordered 1000 draw values of the posterior distribution. Findings: Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared with the 1990–2010 time period, with the greatest annualised rate of decline occurring in the 0–9-year age group. Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough (ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked tenth). In adolescents aged 10–24 years, three injury causes were among the top causes of DALYs: road injuries (ranked first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10–24 years were also in the top ten in the 25–49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain (fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the top-ranked causes of DALYs in both the 50–74-year and 75-years-and-older age groups. Since 1990, there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries. In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI. Interpretation: As disability becomes an increasingly large component of disease burden and a larger component of health expenditure, greater research and development investment is needed to identify new, more effective intervention strategies. With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of universal and more geographically specific influences on health reinforces the need for regular reporting on population health in detail and by underlying cause to help decision makers to identify success stories of disease control to emulate, as well as opportunities to improve. Funding: Bill & Melinda Gates Foundation.

This record has no associated files available for download.

More information

Published date: 17 October 2020
Additional Information: Funding Information: I N Ackerman reports grants from Victorian Government, outside of the submitted work. C A T Antonio reports personal fees from Johnson & Johnson (Philippines), outside of the submitted work. E Beghi reports grants from Italian Ministry of Health and SOBI and personal fees from Arvelle Therapeutics, outside of the submitted work. Y Béjot reports personal fees from AstraZeneca, Bristol Myers Squibb, Pfizer, and Medtronic, Merck Sharpe & Dohme, and Amgen; grants and personal fees from Boehringer-Ingelheim; personal fees and non-financial support from Servier; and non-financial support from Biogen, outside of the submitted work. P S Briant reports personal fees from WHO, outside of the submitted work. H Christensen reports personal fees from Bristol Myers Squibb, Bayer, and Boehringer Ingelheim, outside of the submitted work. L Degenhardt reports grants from Indivior and Seqirus, outside of the submitted work. S J Dunachie reports grants from the Fleming Fund at the UK Department of Health and Social Care, during the conduct of the study. L M Haile reports personal fees from WHO, outside of the submitted work. S M S Islam reports grants from National Heart Foundation of Australia and Deakin University, during the conduct of the study. S L James reports grants from Sanofi Pasteur and employment from Genentech, outside of the submitted work. P Jeemon reports and Clinical and Public Health intermediate fellowship (grant number IA/CPHI/14/1/501497) from the Wellcome Trust—Department of Biotechnology, India Alliance (2015–2020). V Jha reports grants from Baxter Healthcare, GlaxoSmithKline, Zydus Cadilla, NephroPlus, and Biocon, outside of the submitted work. J J Jozwiak reports personal fees from Amgen, ALAB Laboratoria, Teva, Synexus, and Boehringer Ingelheim, outside of the submitted work. S V Katikireddi reports grants from NRS Senior Clinical Fellowship, Scottish Government Chief Scientist Office, and the UK Medical Research Council, during the conduct of the study. S Lewington reports grants from the UK Medical Research Council and the CDC Foundation (with support from Amgen), outside of the submitted work. K J Looker reports grants from WHO and GlaxoSmithKline, outside of the submitted work. S Lorkowski reports personal fees from Akcea Therapeutics, Amedes, Amgen, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, Synlab, Unilever, and Upfield and non-financial support from Preventicus, outside of the submitted work. R A Lyons reports grants from Health Data Research UK, outside of the submitted work. J Massano reports personal fees from Abbvie, Bial, Merck Sharp & Dohme, and Zambon and other support from Boston Scientific, GE Healthcare, Medtronic, and Roche, outside of the submitted work. W Mendoza is a Program Analyst in Population and Development at the UN Population Fund Country Office in Peru, an institution that does not necessarily endorse this study. M Moradi-Lakeh reports personal fees from Novartis, outside of the submitted work. J F Mosser reports grants from the Bill & Melinda Gates Foundation, during the conduct of the study. S Nomura reports grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology. S B Patten reports funding from the Cuthbertson & Fischer Chair in Pediatric Mental Health, during the conduct of the study. T Pilgrim reports grants and personal fees from Biotronik and Boston Scientific, grants from Edwards Lifesciences, and personal fees from HighLife SAS for his work as a member of clinical event committee for a study sponsored by HighLife SAS, outside of the submitted work. M J Postma reports grants and personal fees from Merck Sharp & Dohme, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Novavax, Bristol Myers Squibb, AstraZeneca, Sanofi, IQVIA, and Seqirus; personal fees from Quintiles, Novartis, and Pharmerit; grants from Bayer, BioMerieux, WHO, EU, FIND, Antilope, DIKTI, LPDP, and Budi; and other support from Ingress Health, PAG, and Asc Academics, outside of the submitted work. E Pupillo reports grants from AIFA, outside of the submitted work. A E Schutte reports personal fees from Omron, Servier, Novartis, Takeda, and Abbott, outside of the submitted work. M G Shrime reports grants from Damon Runyon Cancer Research Foundation and Mercy Ships, outside of the submitted work. J A Singh reports personal fees from Crealta/Horizon, Medisys, Fidia, UBM, Trio Health, Medscape, WebMD, Clinical Care Options, Clearview Healthcare Partners, Putnam Associates, Spherix, Practice Point Communications, National Institutes of Health, and the American College of Rheumatology; personal fees from Simply Speaking; other support from Amarin Pharmaceuticals and Viking Pharmaceuticals; and non-financial support from the steering committee of OMERACT (an international organisation that develops measures for clinical trials and receives arm's length funding from 12 pharmaceutical companies), US Food and Drug Administration, Arthritis Advisory Committee, Veterans Affairs Rheumatology Field Advisory Committee, and the editor and director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis, outside of the submitted work. S T S Skou reports personal fees from Journal of Orthopaedic & Sports Physical Therapy and Munksgaard and grants from The Lundbeck Foundation, outside of the submitted work; and being co-founder of GLA:D. GLA:D is a non-profit initiative hosted at University of Southern Denmark aimed at implementing clinical guidelines for osteoarthritis in clinical practice. J D Stanaway reports grants from Bill & Melinda Gates Foundation, during the conduct of the study. R Uddin reports travel and accommodation reimbursement from Deakin University Institute for Physical Activity and Nutrition, outside of the submitted work. All other authors declare no competing interests. Publisher Copyright: © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

Identifiers

Local EPrints ID: 475691
URI: http://eprints.soton.ac.uk/id/eprint/475691
ISSN: 0140-6736
PURE UUID: 929b348e-7993-40b5-9482-77bd1fd29126
ORCID for Paul Lee: ORCID iD orcid.org/0000-0002-5729-6450

Catalogue record

Date deposited: 24 Mar 2023 17:57
Last modified: 14 Jun 2024 02:07

Export record

Altmetrics

Contributors

Author: Cristiana Abbafati
Author: Kaja M. Abbas
Author: Mohsen Abbasi-Kangevari
Author: Foad Abd-Allah
Author: Ahmed Abdelalim
Author: Mohammad Abdollahi
Author: Ibrahim Abdollahpour
Author: Kedir Hussein Abegaz
Author: Hassan Abolhassani
Author: Victor Aboyans
Author: Lucas Guimarães Abreu
Author: Michael R.M. Abrigo
Author: Ahmed Abualhasan
Author: Laith Jamal Abu-Raddad
Author: Abdelrahman I. Abushouk
Author: Maryam Adabi
Author: Victor Adekanmbi
Author: Abiodun Moshood Adeoye
Author: Olatunji O. Adetokunboh
Author: Davoud Adham
Author: Shailesh M. Advani
Author: Ashkan Afshin
Author: Gina Agarwal
Author: Seyed Mohammad Kazem Aghamir
Author: Anurag Agrawal
Author: Tauseef Ahmad
Author: Keivan Ahmadi
Author: Mehdi Ahmadi
Author: Hamid Ahmadieh
Author: Muktar Beshir Ahmed
Author: Temesgen Yihunie Akalu
Author: Rufus Olusola Akinyemi
Author: Tomi Akinyemiju
Author: Blessing Akombi
Author: Chisom Joyqueenet Akunna
Author: Fares Alahdab
Author: Ziyad Al-Aly
Author: Khurshid Alam
Author: Samiah Alam
Author: Tahiya Alam
Author: Fahad Mashhour Alanezi
Author: Turki M. Alanzi
Author: Biresaw Wassihun Alemu
Author: Peter W. Gething
Author: Md Mehedi Hasan
Author: Yang Liu
Author: Nicholas L.S. Roberts
Author: Joshua A. Salomon
Author: Yuan Pang Wang
Author: Stephen S. Lim
Author: Paul Lee ORCID iD
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×